Sean Nolan gath­ers AveX­is alum­ni to launch an­oth­er biotech. Is it an­oth­er race-to-IPO?

5 years ago
Startups
R&D

Covid-19 roundup: Pfiz­er/BioN­Tech shot just as ef­fec­tive in re­al world, study says, as pair preps vari­ant boost­er ...

5 years ago
Coronavirus

Biden is look­ing be­yond Wood­cock or Sharf­stein for FDA com­mis­sion­er — re­port

5 years ago
People
FDA+

Glax­o­SmithK­line re­thinks strat­e­gy for Covid-19 an­ti­body — not the Vir ones — af­ter tri­al flop. Is there hope in ...

5 years ago
R&D
Coronavirus

Flag­ship up­start Cel­lar­i­ty gath­ers $123M to fi­nance its ex­plo­ration of cell be­hav­ior, blaz­ing a new path to build­ing ...

5 years ago
Financing
Startups

Mod­er­na's Stéphane Ban­cel plans to dou­ble down on vac­cine pro­duc­tion, new vari­ants as mR­NA rules in pan­dem­ic fight

5 years ago
R&D

Xilio Ther­a­peu­tics eyes the fast track to the clin­ic with $95M in in­vestor cash to test re­designed IL-2, CT­LA-4 meds

5 years ago
Financing

Ku­ra tees up its lead drug with a 'break­through' at the FDA; NCI teams up with Cy­brexa on pep­tide drug con­ju­gate

5 years ago
News Briefing

In the biggest CRO takeover in years, Icon doles out $12B for PRA Health Sci­ences to fo­cus on de­cen­tral­ized clin­i­cal ...

5 years ago
Deals

With No­vavax vac­cine deal un­der its belt, SK Bio­science plots out March IPO on the Ko­re­an ex­change

5 years ago
Manufacturing

Jeff Hat­field as­sem­bles a syn­di­cate with some A-list pub­lic in­vestors in the mix as Vi­vid­ion adds $135M raise

5 years ago
Financing
Bioregnum

FDA re­view­ers en­dorse J&J sin­gle-dose shot, lay­ing path for 3rd US vac­cine

5 years ago
FDA+

In­dus­try lead­ers need to speak out now more than ever

5 years ago
Biotech Voices

In­sil­i­co preps first can­di­date for IND stud­ies, hop­ing to launch tri­al in IPF by end of 2021

5 years ago
AI

Japan's Soft­Bank plots bil­lions in biotech in­vest­ments in move that could keep the val­u­a­tion flood ris­ing — re­port

5 years ago
People
Financing

Six years sep­a­rat­ed from a ra­bies vac­cine scan­dal, Chi­na’s Yisheng­Bio grabs $130M to go big in in­fec­tious dis­eases, ...

5 years ago
Financing
China

Covid-19 roundup: CanSi­no sub­mits vac­cine to Chi­nese reg­u­la­tors; As­traZeneca says an­ti­bod­ies show ear­ly ef­fi­ca­cy ...

5 years ago
Coronavirus

The mR­NA era is here. MPM be­lieves the fu­ture be­longs to oR­NA — and Big Phar­ma wants a seat at the ta­ble

5 years ago
Startups
Cell/Gene Tx

Pfiz­er gets an FDA fast-pass for an old vac­cine with po­ten­tial mil­i­tary ap­pli­ca­tions

5 years ago
FDA+

It's of­fi­cial: FDA clamps a hold on blue­bird's trou­bled Lenti­Glo­bin pro­gram while EMA con­sid­ers new mea­sures

5 years ago
FDA+

Covid-19 man­u­fac­tur­ing roundup: As­traZeneca strug­gling to make planned vac­cine de­liv­er­ies to EU; J&J out­lines plans ...

5 years ago
Manufacturing

UCB builds on re­la­tion­ship with Mi­crosoft with new AI deal; Sanofi part­ners with Ger­man AAV vec­tor biotech

5 years ago
News Briefing

Bris­tol My­ers scales up cell ther­a­py pro­duc­tion with liso-cel nod in hand and an­oth­er ap­proval maybe on the way

5 years ago
Cell/Gene Tx
Manufacturing

Biotech up­start adds a failed Mer­ck KGaA drug to the pipeline, map­ping new com­bo ap­proach to MAPK path­way

5 years ago
Deals
First page Previous page 730731732733734735736 Next page Last page
A service from the Financial Times